BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology (Oxford) 2020;59:iii84-94. [PMID: 32348510 DOI: 10.1093/rheumatology/kez570] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Akiyama M, Takanashi S, Takeuchi T, Kaneko Y. Salivary gland involvement in ANCA-associated vasculitis. Autoimmun Rev 2021;20:102940. [PMID: 34509652 DOI: 10.1016/j.autrev.2021.102940] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vaglio A, Maritati F, Zwerina J. Response to: 'Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease' by Akiyama et al. Ann Rheum Dis 2020:annrheumdis-2020-218174. [PMID: 32591358 DOI: 10.1136/annrheumdis-2020-218174] [Reference Citation Analysis]
3 Mescia F, Egan AC, Cheema K, Sivasothy P, Jayne DRW. Eosinophilic granulomatosis with polyangiitis present and future. Rheumatology (Oxford) 2021;60:iii24-7. [PMID: 34137880 DOI: 10.1093/rheumatology/keab033] [Reference Citation Analysis]
4 Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev 2021;20:102737. [PMID: 33340770 DOI: 10.1016/j.autrev.2020.102737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sato M, Yoshida Y, Sugimoto T, Kishimoto S, Omoto T, Watanabe H, Tokunaga T, Yukawa K, Kohno H, Mokuda S, Nojima T, Hirata S, Sugiyama E. Asymptomatic coronary aneurysms in a patient with eosinophilic granulomatosis with polyangiitis who developed a digital gangrene. Mod Rheumatol Case Rep 2021;5:130-6. [PMID: 32791887 DOI: 10.1080/24725625.2020.1810404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Egan AC, Smith RM, Jayne DRW. Introduction to the European Vasculitis Society 3rd International Vasculitis Course (Cambridge) case-based supplement. Rheumatology (Oxford) 2021;60:iii1-5. [PMID: 34137887 DOI: 10.1093/rheumatology/keab331] [Reference Citation Analysis]
7 Akiyama M, Kaneko Y, Takeuchi T. Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease. Ann Rheum Dis. [DOI: 10.1136/annrheumdis-2020-218124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Guillevin L. Treatment of systemic necrotizing vasculitides: The 40-year experience of the French Vasculitis Study Group. Presse Med 2020;49:104034. [PMID: 32650043 DOI: 10.1016/j.lpm.2020.104034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Higashitani K, Yoshimi R, Sato Y, Watanabe T, Ihata A. Rituximab and Mepolizumab Combination Therapy for Glucocorticoid-Resistant Myocarditis Related to Eosinophilic Granulomatosis With Polyangiitis. Mod Rheumatol Case Rep 2021:rxab022. [PMID: 34473835 DOI: 10.1093/mrcr/rxab022] [Reference Citation Analysis]